Company:  AEGLEA BIOTHERAPEUTICS, I ... (AGLE)
Form Type:  8-K
Filing Date:  4/21/2017 
CIK:  0001636282 
Address:  901 S. MOPAC EXPRESSWAY, STE. 250
BARTON OAKS PLAZA ONE
 
City, State, Zip:  AUSTIN, Texas 78746 
Telephone:  (512) 942-2935 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$7.15  
Change: 
0.19 (2.73%)  
Trade Time: 
Apr 28  
Market Cap: 
$96.18M
Trade AGLE now with

© 2017  
Description of Business
We are a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. Our engineered human enzymes are designed to degrade specific amino acids in the blood to target these diseases. In inborn errors of metabolism, or IEM, a subset of rare genetic diseases, we are seeking to reduce the toxic levels of amino acids in patients to the normal range. In oncology, we are seeking to reduce amino acid blood levels below the normal range where we believe we will be able to exploit the dependence of certain cancers on specific amino acids. Our lead product candidate, AEB1102 (pegzilarginase), is engineered to degrade the amino acid arginine and is being developed to treat two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers which have been shown to have a metabolic dependence on arginine.
Register and access this filing in:     
  FORM 8-K
    SECTION 7 REGULATION FD
      Item 7.01 Regulation FD Disclosure.
    SIGNATURE